Wedbush Maintains Bullish View on Apple (AAPL) despite AI Delay Concerns
Apple Inc. (NASDAQ:AAPL) is included among the 14 Best Warren Buffett Dividend Stocks to Buy.
On February 17, Wedbush maintained an Outperform rating on Apple Inc. (NASDAQ:AAPL), with a $350 price target. The firm said that the stock has declined in recent weeks as investors worried that some of its expected AI upgrades, especially those tied to Siri, could be delayed. The firm noted that investors have been frustrated after watching what it called a “soap opera” over the past year, reflecting ongoing concerns about Cupertino’s AI direction. Despite this, Wedbush believes the recent pullback is not justified. The firm said the priority for Apple is getting its AI strategy right, and it still expects the company to roll out its more advanced AI features by the summer. That timeline, in Wedbush’s view, remains on track.
At the same time, Apple is continuing to develop new AI-focused hardware. According to a February 17 Bloomberg report, the company is speeding up work on three wearable devices as part of its broader push into AI-powered products. This reflects a wider shift across the tech industry, with companies like OpenAI and Meta Platforms also investing in similar technologies.
People familiar with the plans said Apple is developing smart glasses, a wearable pendant that can be clipped to clothing or worn around the neck, and AirPods with expanded AI capabilities. These devices will be built around Siri, which will use visual context to better understand user needs and carry out tasks. The products will connect to the iPhone and rely on camera systems with different levels of capability. The people shared the information anonymously because the plans have not been publicly announced. Apple declined to comment.
Apple Inc. (NASDAQ:AAPL) is a major technology company that designs, manufactures, and sells consumer electronics, software, and digital services worldwide.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
